CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BTG plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BTG plc
5 Fleet Place
Phone: +44 2075750000p:+44 2075750000 London, EC4M 7RD  United Kingdom Ticker: BTGYYBTGYY

This company was Merged or Acquired on 8/19/2019.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
BTG plc is medical device development and healthcare service provider. It provides Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care and licensing business. It operates through three segments: Interventional Medicine, Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20193/31/2019Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Executive Director Dame PamelaLouise Makin 10/19/2004 10/19/2004
Chief Financial Officer, Executive Director DuncanKennedy 1/1/2018 1/1/2018
General Counsel, Head of Strategic Affairs, Company Secretary PaulMussenden 3/18/2010 3/18/2010
5 additional Officers and Directors records available in full report.

Business Names
Business Name
BGC
Biocompatibles Inc.
Biocompatibles International Limited
27 additional Business Names available in full report.

General Information
Number of Employees: 1,547 (As of 3/31/2019)
Outstanding Shares: 388,257,291 (As of 8/6/2019)
Shareholders: 7,581
Stock Exchange: LON
Fax Number: +44 2075750010


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 06, 2019